

RECEIVED
CENTRAL FAX CENTER

FEB 21 2006

HEXION

Specialty Chemicals


Hexlon Specialty Chemicals, Inc.

1600 Smith Street, 24th Floor
Houston, TX 77002
hexlonchem.com**TOTAL PAGES -6-**

DATE: February 21, 2006

TO: Examiner Bryan A. Fuller
PHONE: (571) 272-8119
FAX: (571) 273-8300FROM: Lisa Kimes Jones
PHONE: (832) 366-2571
FAX: (817) 375-2768RE: USSN: 10/507,301
Filing Date: 09/08/2004
Attorney Docket: BE02021.USCERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence, consisting of a Response to an Office Action dated November 22, 2005 (5 pages), is being facsimile transmitted to the United States Patent and Trademark Office, facsimile number (571) 273-8300 on Tuesday, February 21, 2006.


Lisa Kimes Jones
Registration No. 41,878FACSIMILE TRANSMISSION

This facsimile may contain CONFIDENTIAL INFORMATION which also may be LEGALLY PRIVILEGED and which is intended only for the use of the Addressee(s) named below. If you are not the intended recipient of this facsimile, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination or copying of this facsimile may be strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile to us at the above address via United States Postal Service. Thank you.

RECEIVED
CENTRAL FAX CENTER**FEB 21 2006****"PATENT"****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/507,301 Confirmation No. 4067
Applicant : Bossaerts, Jan D. *et al.*
Filed : September 8, 2004
Art Unit : 3676
Examiner : FULLER, Bryan A.

Docket No. : BE02021.US
Customer No. : 33249

Date : February 21, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

RESPONSE UNDER 37 CFR § 1.111 to OFFICE ACTION
DATED NOVEMBER 22, 2005

Dear Sir:

This is in response to the United States Patent and Trademark Office Action mailed November 22, 2005, regarding the above referenced application.

Amendments to the claims begin on page 2 of this submission.

Remarks begin on page 4 of this submission.